2. Anti-infection Stem Cell/Wnt PI3K/Akt/mTOR Cell Cycle/DNA Damage Epigenetics
  3. Bacterial Antibiotic GSK-3 Aurora Kinase
  4. Ceftriaxone

Ceftriaxone  (Synonyms: Ro 13-9904 free acid)

Cat. No.: HY-B0712 Purity: 99.87%
COA
SDS
Handling Instructions Technical Support

Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis.

For research use only. We do not sell to patients.

CAS No. : 73384-59-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 16 publication(s) in Google Scholar

Other Forms of Ceftriaxone:

Ceftriaxone Related Antibodies

Top Publications Citing Use of Products

    Ceftriaxone purchased from MedChemExpress. Usage Cited in: AMB Express. 2024 Dec 24;14(1):141.  [Abstract]

    Combinational antimicrobial effects between PVB and conventional antibiotics against MRSA ATCC 43,300. TET, Tetracycline. DOX, Doxycycline. E, Erythromycin. AZI, Azithromycin. P, Penicillin. CAZ, Ceftazidime. AMP, Ampicillin. CEZ, Cefazolin. CEF, Cefotaxime. OXA, Oxacillin. CRO, Ceftriaxone. AMK, Amikacin. GEN, Gentamycin, KANA, Kanamycin. TOB, Tobramycin. SPC, Spectinomycin.

    View All Antibiotic Isoform Specific Products:

    View All Isoforms
    Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

    View All GSK-3 Isoform Specific Products:

    View All Isoforms
    GSK-3 GSK-3α GSK-3β

    View All Aurora Kinase Isoform Specific Products:

    View All Isoforms
    Aurora Kinase Aurora A Aurora B Aurora C

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities. Ceftriaxone can be used in the study of bacterial infections and meningitis[1][2][3][4][5][6][7].

    IC50 & Target

    β-lactam

     

    Cellular Effect
    Cell Line Type Value Description References
    CHO IC50
    153.8 μM
    Compound: ceftriaxone
    Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
    Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
    		[PMID: 23812503]
    S2 IC50
    840 μM
    Compound: Ceftriaxone
    TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells
    TP_TRANSPORTER: inhibition of PAH uptake in OAT1-expressing S2 cells
    		[PMID: 12005172]
    S2 IC50
    > 2000 μM
    Compound: Ceftriaxone
    TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells
    TP_TRANSPORTER: inhibition of Estrone sulfate uptake in OAT3-expressing S2 cells
    		[PMID: 12005172]
    In Vitro

    Ceftriaxone (100 μM, 24 h) protects MPP+ treated astrocytes by inhibiting the NF-κB/JNK/c-Jun signaling pathway [3].
    Ceftriaxone (500 μM, 24-48 h) effectively inhibits unanchored cell growth in A549, H520 and H1650 lung cancer cells by inhibiting Aurora B[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ceftriaxone Related Antibodies

    Cell Viability Assay[3]

    Cell Line: Astrocyte
    Concentration: 100 μM
    Incubation Time: 24 h
    Result: Improved cell viability and increased glutamate uptake after MPP+ expose.

    Western Blot Analysis[3]

    Cell Line: Astrocyte
    Concentration: 100 μM
    Incubation Time: 24 h
    Result: Enhanced GLT-1 and GFAP expression.
    Decreased the expression of p-p50, p-IKKα, p-Relb.
    Decreased the number of TUNEL-positive cells.
    In Vivo

    Ceftriaxone (200 mg/kg Intraperitoneal injection for 6 weeks) improves functional markers and oxidative stress and inflammation parameters in a rat model of D-galactose (DGL) -induced liver and kidney injury[5].
    Ceftriaxone (200, 400 mg/kg, Intraperitoneal injection) has a protective effect on convulsion induced by Pentylenetetrazol (PTZ) and PTZ-related oxidative damage in rats[6].
    Ceftriaxone (100, 200 mg/kg, Intraperitoneal injection) reduces mechanical dysodynia and hyperalgesia by activating GLT-1 in Streptozocin (HY-13753)-induced diabetic rat models[7].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: DGL-induced rat model[5]
    Dosage: 200 mg/kg
    Administration: i.p.
    Result: Reduced the BUN, Cr, AST and ALT levels.
    Attenuated the MDA levels and enhanced GPx and CAT activities.
    Reduced the levels of IL-1β and TNF-α mRNA.
    Animal Model: PTZ-induced rat model[6]
    Dosage: 200, 400 mg/kg
    Administration: i.p. 60 min before to PTZ (70 mg/kg)
    Result: Both of the two ceftriaxone groups had lower spike percentages than the saline group.
    Significantly lower MDA levels and higher SOD activity in 200 and 400 mg/kg.
    Clinical Trial
    Molecular Weight

    554.58

    Formula

    C18H18N8O7S3
    CAS No.
    Appearance

    Solid

    Color

    Off-white to yellow

    SMILES

    O=C(C(N12)=C(CSC(N(C)NC3=O)=NC3=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 31.25 mg/mL (56.35 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.8032 mL 9.0158 mL 18.0317 mL
    5 mM 0.3606 mL 1.8032 mL 3.6063 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (4.51 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (4.51 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.87%

    SDS (396 KB)

    COA (254 KB) HNMR (314 KB) RP-HPLC (225 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.8032 mL 9.0158 mL 18.0317 mL 45.0792 mL
    5 mM 0.3606 mL 1.8032 mL 3.6063 mL 9.0158 mL
    10 mM 0.1803 mL 0.9016 mL 1.8032 mL 4.5079 mL
    15 mM 0.1202 mL 0.6011 mL 1.2021 mL 3.0053 mL
    20 mM 0.0902 mL 0.4508 mL 0.9016 mL 2.2540 mL
    25 mM 0.0721 mL 0.3606 mL 0.7213 mL 1.8032 mL
    30 mM 0.0601 mL 0.3005 mL 0.6011 mL 1.5026 mL
    40 mM 0.0451 mL 0.2254 mL 0.4508 mL 1.1270 mL
    50 mM 0.0361 mL 0.1803 mL 0.3606 mL 0.9016 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Ceftriaxone Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Ceftriaxone73384-59-5Ro 13-9904BacterialAntibioticGSK-3Aurora KinaseGlycogen synthase kinase-3Glycogen synthase kinase 3GSK3βAurora BAstrocyteA549DGL-induced rat modelPTZ-induced rat modelInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Ceftriaxone
    Cat. No.:
    HY-B0712
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (396 KB) Français - FR (396 KB) Deutsch - DE (396 KB) Norwegian - NO (396 KB) Español - ES (396 KB) Swedish - SV (396 KB) Italian - IT (396 KB) Korean - KR (396 KB) Portuguese - PT (396 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.